9:49 PM
admin
Ambit Biosciences, which is developing small molecule therapeutics for the treatment of acute myeloid leukemia
, raised $65 million by offering 8.1 million shares at $8. Ambit Biosciences plans to list on the NASDAQ under the symbol AMBI. Ambit Biosciences initially filed confidentially on 12/20/2012. Citi and Leerink Swann acted as joint bookrunners on the deal.
source
please give me comments thanks
, raised $65 million by offering 8.1 million shares at $8. Ambit Biosciences plans to list on the NASDAQ under the symbol AMBI. Ambit Biosciences initially filed confidentially on 12/20/2012. Citi and Leerink Swann acted as joint bookrunners on the deal.
source
please give me comments thanks
0 comments:
Post a Comment